Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $1.78 Million - $2.71 Million
-30,467 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $650,059 - $987,022
-15,805 Reduced 34.16%
30,467 $1.86 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $1.2 Million - $2 Million
46,272 New
46,272 $1.92 Million
Q4 2019

Feb 14, 2020

SELL
$60.18 - $154.77 $137,451 - $353,494
-2,284 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $320,422 - $433,868
2,284 New
2,284 $320,000
Q3 2018

Nov 14, 2018

SELL
$138.11 - $169.04 $14.5 Million - $17.7 Million
-104,899 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $14.7 Million - $18.4 Million
104,899 New
104,899 $16.4 Million
Q1 2018

May 15, 2018

SELL
$152.15 - $192.33 $336,251 - $425,049
-2,210 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$60.72 - $167.34 $126,297 - $348,067
-2,080 Reduced 48.48%
2,210 $363,000
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $263,406 - $379,750
4,290
4,290 $268,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Paloma Partners Management CO Portfolio

Follow Paloma Partners Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.